Making method of mammary gland disease prevention and treatment fabric

A breast disease and fabric technology, which is applied in textiles, papermaking, and fiber processing, can solve problems such as discomfort, poor air permeability, and skin allergies, and achieve the effects of ensuring aesthetics, improving slow-release performance, and ensuring comfort

Active Publication Date: 2014-11-05
重庆蒙特莱蒂服装有限责任公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] 2. Medicinal chest patch, this method has poor air permeability, which brings discomfort to people, and there is also the possibility of skin allergies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Making method of mammary gland disease prevention and treatment fabric
  • Making method of mammary gland disease prevention and treatment fabric
  • Making method of mammary gland disease prevention and treatment fabric

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] The described receiving solution containing microcapsules adopts the following specific preparation steps:

[0063] a) Prepare a polyurethane wall material solution with a mass fraction of 3.8% by polyurethane wall material and dimethylformamide (DMF) solvent;

[0064] b) The main drug tamoxifen drug transdermal agent propylene glycol core material is prepared into solutions with a mass fraction of 3% and 45% respectively, and then the selected main drug tamoxifen, drug transdermal agent propylene glycol core material and polyurethane The wall material solution is subjected to high-voltage electric spraying through the three-way pipe fittings according to the method described in the above step 1.3), and 20Kv DC high-voltage static electricity is applied;

[0065] c) Use a micro-injection pump to spray from the needle of the dispensing needle. The flow rate of the external liquid is 1.5mL / h, and the flow rate of the two internal liquids is 0.75mL / h. It is received by dis...

Embodiment 2

[0070] The described receiving solution containing microcapsules adopts the following specific preparation steps:

[0071] a) Prepare a polyurethane wall material solution with a mass fraction of 3.3% by polyurethane wall material and dimethylformamide (DMF) solvent;

[0072] b) Prepare the main drug tamoxifen drug transdermal agent propylene glycol core material into solutions with a mass fraction of 1% and 10% respectively, and then use the high-voltage electrospray method to mix the selected main drug tamoxifen, drug transdermal agent propylene glycol core material and polyurethane The wall material solution is subjected to high-voltage electric spraying through the three-way pipe fittings according to the method described in the above step 1.3), and 20Kv DC high-voltage static electricity is applied;

[0073] c) Use a micro-injection pump to spray from the needle of the dispensing needle. The flow rate of the external liquid is 0.5mL / h, and the flow rate of the two interna...

Embodiment 3

[0078] The described receiving solution containing microcapsules adopts the following specific preparation steps:

[0079] a) Prepare a polyurethane wall material solution with a mass fraction of 3.5% of the polyurethane wall material and dimethylformamide (DMF) solvent;

[0080] b) The main drug tamoxifen drug transdermal agent propylene glycol core material is prepared into solutions with mass fractions of 2% and 25% respectively, and then the selected main drug tamoxifen, drug transdermal agent propylene glycol core material and polyurethane The wall material solution is subjected to high-voltage electric spraying through the three-way pipe fittings according to the method described in the above step 1.3), and 20Kv DC high-voltage static electricity is applied;

[0081] c) Use a micro-injection pump to spray from the needle of the dispensing needle. The flow rate of the external liquid is 1.2mL / h, and the flow rate of the two internal liquids is 0.6mL / h. It is received by d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a making method of a mammary gland disease prevention and treatment fabric. The method comprises the following steps: preparing a bi-component microcapsule, receiving through a non-solvent solution to obtain a microcapsule-containing reception solution including a tamoxifen core used for preventing and treating the mammary gland disease and a propylene glycol core used for medicinal percutaneous absorption; centrifuging, cleaning, centrifuging, and drying at normal temperature to obtain microcapsule powder; preparing a microcapsule finishing liquid, and adding a sticking agent and an organosilicon softener; and selecting a knitted fabric as a base cloth, and carrying out an immersion process to obtain the mammary gland disease prevention and treatment fabric. The underwear fabric made in the invention is comfortable and soft, can prevent and treat the mammary gland disease, makes tamoxifen and propylene glycol simultaneously coated, the microcapsule particle size small and tamoxifen and propylene glycol slowly released in appropriate proportion, is convenient, safe and mild through the percutaneous drug delivery, and has good patient compliance; the adoption of the knitted fabric improves the durability and the washing fastness, and the mammary gland disease prevention and treatment fabric has an internal disease external treatment efficacy; and the mammary gland disease prevention and treatment has the advantages of simple process, good repeatability and good application prospect.

Description

technical field [0001] The invention relates to a preparation method of a fabric, in particular to a preparation method of a fabric for preventing and treating mammary gland diseases. Background technique [0002] Breast disease is one of the main diseases that endanger women's health at this stage. In China, the age of onset of mammary gland hyperplasia is mostly between 20 and 44 years old, and the incidence rate accounts for about 40% of women of childbearing age, accounting for about 70% to 78% of breast diseases. %. About 2% to 3% of patients develop cancer. For the treatment of this type of disease, traditional Chinese medicine adopts the method of oral administration and external application, and the treatment process is more loaded down with trivial details and time-consuming. In Western medicine clinical practice, oral administration is mostly adopted, but due to the short release time of the tamoxifen drug, it is highly irritating to the stomach. The combination...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): D06M23/12
Inventor 邹奉元杜磊徐瑶瑶彭微微
Owner 重庆蒙特莱蒂服装有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap